Bone Biologics is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX®. The NELL-1/DBX® combination product is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The protein, as part of the UCB-1 technology platform has been licensed for worldwide applications to Co. through a technology transfer from UCLA Technology Development Group. Co.'s platform technology has application in delivering outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. We show 12 historical shares outstanding datapoints in our coverage of BBLG's shares outstanding history.
Understanding the changing numbers of BBLG shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BBLG versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BBLG by allowing them to research BBLG shares outstanding history
as well as any other stock in our coverage universe. |
Free BBLG Email Alerts:
Video: Shares Outstanding Importance
